Cationic antimicrobial peptides as potential new therapeutic agents in neonates and children: A review

Current Opinion in Infectious Diseases

Volumn 27, Issue 3, 2014, Pages 258-267

  Ashby, Martin ^a   Petkova, Asya ^a   Hilpert, Kai ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

antibiotics; antimicrobial peptides; host defence peptides; infection; resistance

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CATIONIC ANTIMICROBIAL PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CARRIER PROTEIN; CATIONIC ANTIMICROBIAL PROTEIN CAP 37, HUMAN; PLASMA PROTEIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ATOPIC DERMATITIS; ENTEROCOCCUS FAECALIS; GROUP B STREPTOCOCCAL INFECTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; IMPATIENS; INFECTION RESISTANCE; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; NOSE SECRETION; PEDIATRICS; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REVIEW; SHIGELLOSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; CHILD; COMMUNICABLE DISEASES; DRUG DESIGN; IMMUNOLOGY; IMMUNOTHERAPY; INFANT; NEWBORN; PRESCHOOL CHILD;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASES; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; INFANT; INFANT, NEWBORN;

EID: 84900478519     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000057     Document Type: Review

References (108)

1. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance: the need for global solutions. Lancet Infect Dis 2013; 13:1057-1098.
2. Kollmann TR, Crabtree J, Rein-Weston A, et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 2009; 183:7150-7160; http://www.ncbi.nlm.nih.gov/pubmed/19917677.
3. Lilic D, Cant AJ, Abinun M, et al. Cytokine production differs in children and adults. Pediatr Res 1997; 42:237-240; http://www.ncbi.nlm.nih.gov/ pubmed/9262229.
4. Mammina C, Di Carlo P, Cipolla D, et al. Surveillance of multidrug-resistant Gram-negative bacilli in a neonatal intensive care unit: prominent role of cross transmission. Am J Infect Control 2007; 35:222-230; http://www.ncbi.nlm. nih.gov/pubmed/17482993.
5. Samanta S, Farrrer K, Breathnach A, Heath PT, et al. Risk factors for late onset Gram-negative infections: a case-control study. Arch Dis Child Fetal Neonatal Ed 2011; 96:F15-F18; http://www.ncbi.nlm.nih.gov/pubmed/20538712.
6. Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67:1607-1615.
7. Saravolatz LD, Pawlak J, Johnson L, et al. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezo-lid-nonsusceptible Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56:4478-4482.
8. Uccelletti D, Zanni E, Marcellini L, et al. Anti-Pseudomonas activity of frog skin antimicrobial peptides in a Caenorhabditis elegans infection model: a plau sible mode of action in vitro and in vivo. Antimicrob Agents Chemother 2010;54:3853-3860.
9. Lipsky BA, Holroyd KJ, Zasloff M, et al. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 2008; 47:1537-1545; http://www.ncbi.nlm.nih.gov/pubmed/18990064.
10. Velden WJFM van der, van Iersel TMP, Blijlevens NMA, Donnelly JP. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med. [Internet]. 2009 Jan [cited 2014 Jan 21];7:44. http://www.pub medcentral.nih.gov/articlerender.fcgi?artid=2746231&tool=pmcentrez& rendertype=Abstract.
11. Alam NH, Raqib R, Ashraf H, et al. L-isoleucine-supplemented oral rehydra-tion solution in the treatment of acute diarrhoea in children: a randomized controlled trial. J Health Popul Nutr 2011; 29:183-190; http://www.pub medcentral.nih.gov/articlerender.fcgi?artid=3131118&tool= pmcentrez& rendertype=Abstr1act.
12. Raqib R, Sarker P, Mily A, et al. Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial. BMC Infect Dis 2012; 12:111; http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=3447723&tool=pmcentrez&rendertype=Abstract.
13. Cherkasov A, Hilpert K, Jenssen H, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem Biol 2009; 4:65-74.
14. Hancock RE, Lehrer R. Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998; 16:82-88; http://www.ncbi.nlm.nih.gov/pubmed/9487736.
15. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001; 1:156-164; http://www.ncbi.nlm. nih.gov/pubmed/11871492.
16. Papo N, Shai Y. Host defense peptides asnew weapons incancer treatment. Cell Mol Life Sci 2005; 62:784-790.
17. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002; 23:291-296; http://www.ncbi.nlm.nih.gov/pubmed/12072367.
18. Fjell CD, Hancock REW, Cherkasov A. AM Per: a database and anautomated discovery tool for antimicrobial peptides. Bioinformatics 2007; 23:1148-1155.
19. Casteels P, Ampe C, Riviere L, et al. Isolation and characterization of abaecin, a major antibacterial response peptide in the honeybee (Apis mellifera). Eur J Biochem 1990; 187:381-386; http://www.ncbi.nlm.nih.gov/pubmed/ 2298215.
20. Soscia SJ, Kirby JE, Washicoky KJ, et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010; 5:e9505; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 2831066&tool= pmcentrez&rendertype=Abstract.
21. Garcia AE, Osapay G, Tran PA, et al. Isolation, synthesis, and antimicrobial activities of naturally occurring theta-defensin isoforms from baboon leukocytes. Infect Immun 2008; 76:5883-5891; http://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=2583559&tool=pmcentrez&rendertype= Abstract.
22. Eisenhauer PB, Harwig SS, Lehrer RI. Cryptdins: antimicrobial defensins of the murine small intestine. Infect Immun 1992; 60:3556-3565; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=257361&tool= pmcentrez& rendertype=Abstract.
23. Marischen L, Wesch D, Schröder JM. Human gammadelta T cells produce the protease inhibitor and antimicrobial peptide elafin. Scand J Immunol 2009; 70:547-552; http://www.ncbi.nlm.nih.gov/pubmed/19906197.
24. Harder J, Bartels J, Cristophers E, Schroder JM. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276:5707-5713; http://www.ncbi.nlm.nih.gov/pubmed/ 11085990.
25. HAMP hepcidin antimicrobial peptide [Homo sapiens (human)]-Gene-NCBI [Internet]. http://www.ncbi.nlm.nih.gov/gene/57817. [Accessed 2014 Jan 20]
26. Wagener J, Schneider JJ, Baxmann S, et al. A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation. J Invest Dermatol 2013; 133:144-153; http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=3488162&tool=pmcentrez&rendertype=Abstract.
27. Selsted ME, Harwig SS, Ganz T, et al. Primary structures of three human neutrophil defensins. J Clin Invest 1985; 76:1436-1439; http://www.pub medcentral.nih.gov/articlerender.fcgi?artid=424095&tool=pmcentrez&ren dertype=Abstract.
28. Cole AM, Kim YH, Tahk S, et al. Calcitermin, a novel antimicrobial peptide isolated from human airway secretions. FEBS Lett 2001; 504:5-10; http://www.ncbi.nlm.nih.gov/pubmed/11522286.
29. Oppenheim FG, Xu T, McMillian FM, et al. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 1988; 263:7472-7477; http://www.ncbi.nlm.nih.gov/pubmed/3286634.
30. Xu L, Lal K, Pollock JJ. Histatins 2 and 4 are autoproteolytic degradation products of human parotid saliva. Oral Microbiol Immunol 1992; 7:127-128; http://www.ncbi.nlm.nih.gov/pubmed/1528633.
31. Hunter HN, Demcoe AR, Jenssen H, et al. Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob Agents Chemother 2005; 49:3387-3395; http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=1196233&tool=pmcentrez &rendertype=Abstract.
32. Kim YS, Lee SK, Park SC, et al. Cloning and identification of a new antimicrobial protein, salvic, from human salivary gland. J Hard Tissue Biol 2005; 14:258-260; http://joi.jlc.jst.go.jp/JST.JSTAGE/jhtb/14.258?from= CrossRef.
33. Gudmundsson GH, Agerberth B, Odeberg J, et al. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 1996; 238:325-332; http://www.ncbi.nlm. nih.gov/pubmed/8681941.
34. Lai R, Zheng YT, Shen JH, et al. Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima. Peptides 2002; 22:427-435; http://www.ncbi.nlm.nih.gov/pubmed/11835991.
35. Duvick JP, Rood T, Rao AG, Marshak DR. Purification and characterization of a novel antimicrobial peptide from maize (Zea mays L.) kernels. J Biol Chem 1992; 267:18814-18820; http://www.ncbi.nlm.nih.gov/pubmed/1527010.
36. Lauth X, Shike H, Burns JC, et al. Discovery and characterization of two isoforms of moronecidin, a novel antimicrobial peptide from hybrid striped bass. J Biol Chem 2002; 277:5030-5039; http://www.ncbi.nlm.nih.gov/pubmed/11739390.
37. Harder J, Bartels J, Cristophers E, et al. Innate immunity. Isolation of several cysteine-rich antimicrobial peptides from the blood of a mollusc, Mytilus edulis. J Biol Chem 1996; 271:21808-21813; http://www.ncbi.nlm.nih. gov/pubmed/8702979.
38. Shimizu M, Shigeri Y, Tatsu Y, et al. Enhancement of antimicrobial activity of neuropeptide Y by N-terminal truncation. Antimicrob Agents Chemother 1998; 42:2745-2746; http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=105930&tool=pmcentrez&rendertype=Abstract.
39. Kowalska K, Carr DB, Lipkowski AW. Direct antimicrobial properties of substance P. Life Sci 2002; 71:747-750; http://www.ncbi.nlm.nih.gov/pubmed/ 12074933.
40. Cuthbertson BJ, Shepard EF, Chapman RW, Gross PS. Diversity of the penaeidin antimicrobial peptides in two shrimp species. Immunogenetics 2002; 54:442-445; http://www.ncbi.nlm.nih.gov/pubmed/12242595.
41. Nissen-Meyer J, Larsen AG, Sletten K, et al. Purification and characterization of plantaricin A, a Lactobacillus plantarum bacteriocin whose activity depends on the action of two peptides. J Gen Microbiol 1993; 139:1973-1978; http://www.ncbi.nlm.nih.gov/pubmed/8245827.
42. Orivel J, Redeker V, Le Caer JP, et al. Ponericins, new antibacterial and insecticidal peptides from the venom of the ant Pachycondyla goeldii. J Biol Chem 2001; 276:17823-17829; http://www.ncbi.nlm.nih.gov/pubmed/11279030.
43. McManus AM, Dawson NF, Wade JD, et al. Three-dimensional structure of RK-1: a novel alpha-defensin peptide. Biochemistry 2000; 39:15757-15764; http://www.ncbi.nlm.nih.gov/pubmed/11123900.
44. Zhao H, Lee W-H, Shen J-H, et al. Identification of novel semenogelin I-derived antimicrobial peptide from liquefied human seminal plasma. Peptides 2008; 29:505-511; http://www.ncbi.nlm.nih.gov/pubmed/18314226.
45. Tack BF, Sawai MV, Kearney WR, et al. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. Eur J Chem 2002; 269:1181-1189; http://www.ncbi.nlm.nih.gov/pubmed/11856344.
46. Goraya J, Wang Y, Li Z, et al. Peptides with antimicrobial activity from four different families isolated from the skins of the North American frogs Rana luteiventris, Rana berlandieri and Rana pipiens. Eur J Biochem 2000; 267:894-900; http://www.ncbi.nlm.nih.gov/pubmed/10651828.
47. Evans EW, Beach GG, Wunderlich J, Harmon BG. Isolation of antimicrobial peptides from avian heterophils. J Leukoc Biol 1994; 56:661-665; http://www.ncbi.nlm.nih.gov/pubmed/7964174.
48. Von Deuster CIE, Knecht V. Antimicrobial selectivity based on zwitterionic lipids and underlying balance of interactions. Biochim Biophys Acta-Biomembr 2012; 1818:2192-2201.
49. Mihajlovic M, Lazaridis T. Charge distribution and imperfect amphipathicity affect pore formation by antimicrobial peptides. Biochim Biophys Acta 2012; 1818:1274-1283.
50. Laughlin TF, Ahmad Z. Inhibition of Escherichia coli ATP synthase by amphibian antimicrobial peptides. Int J Biol Macromol 2010; 46:367-374.
51. Hilpert K, McLeod B, Yu J, et al. Short cationic antimicrobial peptides interact with ATP. Antimicrob Agents Chemother 2010; 54:4480-4483.
52. Rossignol J-M, Jacquet M, Arimondo P, et al. The action of the bacterial toxin, microcin B17, on DNA gyrase. Biochimie 2007; 89:500-507.
53. Yount NY, Yeaman MR. Peptide antimicrobials: cell wall as a bacterial target. Ann N Y Acad Sci 2013; 1277:127-138.
54. Gantt S, Muller WJ. The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention. Clin Dev Immunol 2013; 2013:369172; http://www.pubmedcentral.nih.gov/articler ender.fcgi?artid=3626239&tool=pmcentrez&rendertype=Abstract.
55. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012; 366:34-43.
56. Vorland LH. Lactoferrin: a multifunctional glycoprotein. APMIS 1999; 107:971-981.
57. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 2005; 62:127-138; http://www.ncbi.nlm.nih.gov/pubmed/16261252.
58. Sinha M, Kaushik S, Kaur P, et al. Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein. Int J Pept 2013; 2013:390230; http://www.pubmedcentral.nih.gov/articlerender.fc-gi? artid=3608178&tool=pmcentrez&rendertype=Abstract.
59. Seganti L, Di Biase M, Rega B, et al. Involvement of bovine lactoferrin moieties in the inhibition of herpes simplex virus type 1 infection. Int J Immunopathol 2001; 14:71-79; http://www.ncbi.nlm.nih.gov/pubmed/12604021.
60. Jenssen H. Anti herpes simplex virus activity of lactoferrin/ lactoferricin-an example of antiviral activity of antimicrobial protein/peptide. Cell Mol Life Sci 2005; 62:3002-3013; http://www.ncbi.nlm.nih.gov/pubmed/ 16261265.
61. Shestakov A, Jenssen H, Nordström I, Eriksson K. Lactoferricin but not lactoferrin inhibit herpes simplex virus type 2 infection in mice. Antiviral Res 2012; 93:340-345; http://www.ncbi.nlm.nih.gov/pubmed/22269645.
62. Capanna F, Emonet SP, Cherkaoui A, et al. Antibiotic resistance patterns among group B Streptococcus isolates: implications for antibiotic prophy laxis for early-onset neonatal sepsis. Swiss Med Wkly 2013; 143:w13778; http://www.ncbi.nlm.nih.gov/pubmed/23572445.
63. Harder J, Bartels J, Christophers E, Schrö der JM. A peptide antibiotic from human skin. Nature 1997; 861.
64. Boldenow E, Jones S, Lieberman RW, et al. Antimicrobial peptide response to group B Streptococcus in human extraplacental membranes in culture. Placenta 2013; 34:480-485; http://www.ncbi.nlm.nih.gov/pubmed/23562109.
65. Zaga-lavellina V, Ruiz M, Flores-Espinosa P, et al. Tissue-specific human beta-defensins (HBD)-1, HBD-2 and HBD-3 secretion profile from human amniochorionic membranes stimulated with Candida albicans in a two-compartment tissue culture system. Reprod Biol Endocrinol 2012; 10:70; http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=3495197&tool= pmcentrez&rendertype=Abstract.
66. Allerberger F, Wagner M. Listeriosis: a resurgent foodborne infection. Clin Microbiol Infect 2010; 16:480-485; http://www.ncbi.nlm.nih.gov/pubmed/ 20002687.
67. Gravesen A, Sørensen K, Aarestrup FM, Knøchel S. Spontaneous nisin-resistant Listeria monocytogenes mutants with increased expression of a putative penicillin-binding protein and their sensitivity to various antibiotics. Microb Drug Resist 2001; 7:127-135; http://www.ncbi.nlm. nih.gov/pubmed/11442339.
68. Babasaki K, Takao T, Shimonishi Y, et al. A new antibiotic peptide produced by Bacillus subtilis 168: isolation, structural analysis, and biogenesis. J Biochem 1985; 98:585-603; http://www.ncbi.nlm.nih.gov/pubmed/ 3936839.
69. Van Kuijk S, Noll KS, Chikindas ML, et al. The species-specific mode of action of the antimicrobial peptide subtilosin against Listeria monocytogenes Scott A. Lett Appl Microbiol 2012; 54:52-58; http://www.ncbi.nlm.nih.gov/pubmed/ 22040458.
70. Zaidi AK, Huskins WC, Thaver D, et al. Hospital-acquired neonatal infections in developing countries. Lancet 2005; 365:1175-1188; http://www.scien cedirect.com/science/article/pii/S014067360571881X.
71. Jefferies JMC, Cooper T, Yam T, Clarke SC. Pseudomonas aeruginosa outbreaks in the neonatal intensive care unit-a systematic review of risk factors and environmental sources. J Med Microbiol 2012; 61:1052-1061; http://www.ncbi.nlm.nih.gov/pubmed/22683659.
72. Hassett DJ, Cuppoletti J, Trapnell B, et al. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 2002; 54:1425-1443; http://www.ncbi.nlm.nih.gov/pubmed/ 12458153.
73. Hirt H, Gorr S-U. Antimicrobial peptide GL13K is effective in reducing biofilms of Pseudomonas aeruginosa. Agents Chemother 2013; 57: 4903-4910; http://www.ncbi.nlm.nih.gov/pubmed/23917321.
74. Chen H-L, Su P-Y, Chang Y-S, et al. Identification of a novel antimicrobial peptide from human hepatitis B virus core protein arginine-rich domain (ARD). PLoS Pathog 2013; 9:e1003425; http://dx.doi.org/10.1371/journal. ppat.1003425.
75. Poh CH, Oh HML, Tan AL. Epidemiology and clinical outcome of enter-ococcal bacteraemia in an acute care hospital. J Infect 2006; 52:383-386; http://www.ncbi.nlm.nih.gov/pubmed/16203039.
76. Cheng VCC, Chan JFW, Tai JWM, et al. Successful control of vancomycin-resistant Enterococcus faecium outbreak in a neurosurgical unit at non-endemic region. Emerg Health Threats J 2009; 2:e9; http://www.pubmed central.nih.gov/articlerender.fcgi?artid=3167649&tool=pmcentrez&render type=Abstract.
77. Fan X, Reichling J, Wing M, et al. Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria. Pharmazie 2013; 68:628-630; http://www.ncbi.nlm.nih.gov/pubmed/23923648.
78. Kim H, Jang JH, Kim SC, Cho JH, et al. De novo generation of short antimicrobial peptides with enhanced stability and cell specificity. J Anti-microb Chemother 2014; 69:121-132; http://www.ncbi.nlm.nih.gov/pubmed/ 23946320.
79. Nelson MU, Gallagher PG. Methicillin-resistant Staphylococcus aureus in the neonatal intensive care unit. Semin Perinatol 2012; 36:424-430; http://www.ncbi.nlm.nih.gov/pubmed/23177801.
80. Park DA, Lee SM, Peck KR, et al. Impact of methicillin-resistance on mortality in children and neonates with Staphylococcus aureus bacteremia: a meta-analysis. Infect Chemother 2013; 45:202-210; http://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=3780954&tool=pmcentrez&rendertype= Abstract.
81. Melo-Cristino J, Resina C, Manuel V, et al. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 2013; 382:205; http://www.ncbi.nlm.nih.gov/pubmed/23791472.
82. Moravvej Z, Estaji F, Askari E, et al. Updateonthe global number ofvancomycin-resistant Staphylococcus aureus (VRSA) strains. Int J Antimicrob Agents 2013; 42:370-371; http://www.ncbi.nlm.nih.gov/pubmed/23880172.
83. Sammons HM, Starkey E. Vancomycin use in neonates and children: evidence-based practice is needed. Arch Dis Child 2013; 98:447-448; http://www.ncbi.nlm.nih.gov/pubmed/23592728.
84. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 2008; 6:17-27; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2211378&tool= pmcentrez&rendertype=Abstract.
85. Nielsen A, Mansson M, Bojer MS, et al. Inhibits quorum sensing and reduces Staphylococcus aureus mediated killing of human neutrophils. PLoS One 2014; 9:e84992; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 3885660&tool=pmcentrez&rendertype=Abstract.
86. Tjabringa GS, Ninaber DK, Drijfhout JW, et al. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int Arch Allergy Immunol 2006; 140:103-112; http://www.ncbi. nlm.nih.gov/pubmed/16557028.
87. Niyonsaba F, Iwabuchi K, Matsuda H, et al. Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol 2002; 14:421-426; http://www.ncbi.nlm.nih.gov/pubmed/11934878.
88. Yang D, Chen Q, Chertov O, Oppenheim JJ, et al. Human neutrophil defen-sins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000; 68:9-14; http://www.ncbi.nlm.nih.gov/pubmed/10914484.
89. Steinstraesser L, Koehler T, Jacobsen F, et al. Host defense peptides in wound healing. Mol Med 2008; 14:528-537; http://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=2277318&tool=pmcentrez&rendertype= Abstract.
90. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111:1665-1672; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=156109&tool= pmcentrez&rendertype=Abstract.
91. Davidson DJ, Currie AJ, Reid GSD, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization.J Immunol 2004; 172:1146-1156; http://www.ncbi.nlm.nih. gov/pubmed/14707090.
92. Semple F, Webb S, Li H-N, et al. Human beta-defensin 3 has immunosup-pressive activity in vitro and in vivo. Eur J Immunol 2010; 40:1073-1078; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 2948537&tool= pmcentrez&rendertype=Abstract.
93. Ghosh SK, Gupta S, Jiang B, Weinberg A, et al. Fusobacterium nucleatum and human beta-defensins modulate the release of antimicrobial chemo-kine CCL20/macrophage inflammatory protein 3a. Infect Immun 2011; 79:4578-4587; http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 3257922&tool= pmcentrez&rendertype=Abstract.
94. Bowdish DME, Davidson DJ, Lau YE, et al. Impact of LL-37 on antiinfective immunity. J Leukoc Biol 2005; 77:451-459; http://www.ncbi.nlm.nih.gov/pubmed/ 15569695.
95. Choi K-Y, Chow LNY, Mookherjee N, et al. Cationic host defence peptides: multifaceted role in immune modulation and inflammation. J Innate Immun 2012; 4:361-370; http://www.ncbi.nlm.nih.gov/pubmed/22739631.
96. Huang H-N, Pan C-Y, Chan Y-L, et al. Use of the antimicrobial peptide pardaxin (GE33) to protect against MRSA infection in mice with skin injuries. Antimicrob Agents Chemother 2013; 58:1-22; http://www.ncbi.nlm.nih.gov/pubmed/ 24366739.
97. Van der Does AM, Bergman P, Agerberth P, Lindbom L. Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections. J Leukoc Biol 2012; 92:735-742; http://www.ncbi.nlm.nih.gov/pubmed/22701042.
98. WHO. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type. 2005; 1:2-6.
99. Islam D, Bandholtz L, Nilsson J, et al. Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med 2001; 7:180-185.
100. Hase K, Eckmann L, Leopard JD, et al. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun 2002; 70:953-963.
101. Raqib R, Sarker P, Bergman P, et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A 2006; 103:9178-9183.
102. Sherman H, Chapnik N, Froy O, et al. Albumin and amino acids upregulate the expression of human beta-defensin 1. Mol Immunol 2006; 43:1617-1623; http://www.ncbi.nlm.nih.gov/pubmed/16263169.
103. Wang T-T, Nestel FP, Bourdeau V, et al. Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 204; 173:2909-2912; http://www.ncbi.nlm.nih.gov/pubmed/ 15322146.
104. Horii KA, Simon SD, Liu DY, Sharma V. Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics 207; 120:e527-e534; http://www.ncbi.nlm.nih.gov/pubmed/17766497.
105. Kamer B, Pasowska R, Dolka E, et al. Prevalence of atopic dermatitis in infants during the first six months of life: authors' observations. Poste py dermatologii i Alergol 2013; 30:277-281; http://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=3858654&tool=pmcentrez&rendertype= Abstract.
106. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347:1151-1160; http://www.ncbi.nlm.nih.gov/pubmed/12374875.
107. Hata DR, Gallo RL. Antimicrobial peptides, skin infections, and atopic dermatitis. Semin Cutan Med Surg 2008; 27:144-150; http://www.pub medcentral.nih.gov/articlerender.fcgi?artid=2546601&tool=pmcentrez& rendertype=Abstract.
108. Hata TR, Audish D, Kotol P, et al. A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis. J Eur Acad Dermatol Venereol 2013; 1-9; http://www.ncbi.nlm.nih.gov/pubmed/23638978 doi: 10.1111/jdv.12176. [Epub ahead of print]